| scholarly article | Q13442814 |
| P2093 | author name string | H Fujii | |
| Y Kawaguchi | |||
| K Kono | |||
| K Mimura | |||
| H Akaike | |||
| H Sugai | |||
| F Mitsui | |||
| P2860 | cites work | A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor | Q24648517 |
| Untangling the ErbB signalling network | Q27860884 | ||
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin | Q34212131 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| ZD1839 (IRESSA): a selective EGFR-TK inhibitor | Q34734513 | ||
| IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer | Q34992242 | ||
| Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody | Q34992262 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies | Q35179415 | ||
| Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma | Q36616556 | ||
| Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma | Q36696088 | ||
| Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas | Q37252270 | ||
| Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels | Q40326009 | ||
| Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. | Q40372888 | ||
| Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma | Q40401124 | ||
| Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. | Q40798689 | ||
| Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden | Q41058655 | ||
| Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. | Q41175271 | ||
| Immunohistologic detection of the epidermal growth factor receptor in human esophageal squamous cell carcinoma | Q42466142 | ||
| Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. | Q43583339 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus | Q44513217 | ||
| Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. | Q44691624 | ||
| Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study | Q47604705 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. | Q52059159 | ||
| EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. | Q53810400 | ||
| Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer | Q57424487 | ||
| Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus | Q57702493 | ||
| Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas | Q69609338 | ||
| Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification | Q72078811 | ||
| Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors | Q72403213 | ||
| Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues | Q72684109 | ||
| Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells | Q72808513 | ||
| Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas | Q73473432 | ||
| ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation | Q73746992 | ||
| Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years | Q74026775 | ||
| HER-2--a possible target for therapy of metastatic urinary bladder carcinoma | Q74658548 | ||
| Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model | Q77555291 | ||
| Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay | Q77925384 | ||
| Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer | Q78386151 | ||
| The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma | Q78961998 | ||
| A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurem | Q80938604 | ||
| EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus | Q81211241 | ||
| Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma | Q81322527 | ||
| Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | Q81414756 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| squamous cell carcinoma | Q681817 | ||
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 494-501 | |
| P577 | publication date | 2007-07-10 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma | |
| P478 | volume | 97 |
| Q35130286 | An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer |
| Q51056791 | Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. |
| Q50053443 | Augmentation of antibody-dependent cellular cytotoxicity with defucosylated monoclonal antibodies in patients with GI-tract cancer |
| Q38262688 | Bioinformatics for cancer immunotherapy target discovery |
| Q39866108 | C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome |
| Q51752513 | Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. |
| Q42361543 | Clinical relevance of histologic subtypes in locally advanced esophageal carcinoma treated with pre-operative chemoradiotherapy: Experience of a monographic oncologic centre. |
| Q38392935 | EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer |
| Q37893414 | Emerging antibody combinations in oncology |
| Q37488281 | Emerging drugs for esophageal cancer |
| Q40971778 | Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence |
| Q37256825 | Esophageal cancer: current and emerging therapy modalities. |
| Q33398141 | Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry |
| Q30498197 | Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity |
| Q37025333 | Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice? |
| Q40062078 | Genetic diagnosis of patients with esophageal cancer using FISH. |
| Q90626593 | HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population |
| Q36213090 | Improving target cell specificity using a novel monovalent bispecific IgG design |
| Q38905987 | In vitro antiproliferative effect of trastuzumab (Herceptin(®)) combined with cetuximab (Erbitux(®)) in a model of human non-small cell lung cancer expressing EGFR and HER2. |
| Q33658562 | Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma |
| Q38221886 | Investigational therapies targeting the ErbB family in oesophagogastric cancer |
| Q39612011 | Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines |
| Q39372385 | Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma |
| Q33715830 | Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer |
| Q26783407 | New developments in atherosclerosis: clinical potential of PCSK9 inhibition |
| Q58110132 | PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models |
| Q42726594 | Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin |
| Q37652493 | Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy |
| Q37594158 | Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus |
| Q54672060 | Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation. |
| Q42154615 | Targeted treatments for metastatic esophageal squamous cell cancer |
| Q42769520 | Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine? |
| Q37941807 | Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma |
| Q40539652 | The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer |
| Q46512633 | Value of targeted therapy for penile cancer |
Search more.